This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD4 IgG to TNF. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD4 as well as the biological activity of TNF. TNF-FuP significantly accumulated in the tumor, which led to retardation of tumor growth. The fusion protein stimulated cytokine production and cytotoxic activity of monocytes and, to a low degree, of T cells. The therapeutic effect was improved by intratumoral application. Importantly, the efficacy of TNF-FuP depended on the induction of an immune response in vivo. This immunocytokine was designed for treating tumor.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-039 | Anti-Human CD4 Recombinant Antibody (Zanolimumab) | Neut, ELISA, IF, IP, FuncS, FC, IHC | IgG1 - kappa |
There are currently no Customer reviews or questions for ACFP-SH123. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.